[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100426453":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":36,"responsibleParty":61,"collaborators":32,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":32,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":85,"whyStopped":32,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Hebei Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Leptomeningeal metastases received EGFR-TKI and Nimotuzumab","EXPERIMENTAL","The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI",[13],"Drug: Nimotuzumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Nimotuzumab","Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks",[9],[21],"EGFR-TKI",[23],{"name":24,"affiliation":25,"role":26},"jiao xue qi, master","The Second Hospital of Hebei Medical University","PRINCIPAL_INVESTIGATOR",[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"hui bu, PhD","CONTACT","0311-66003711-211",null,"buhuimy1@163.com",{"name":24,"role":30,"phone":32,"phoneExt":32,"email":35},"1074234012@qq.com",[37,54],{"facility":25,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Hebei","Shijiazhuang\u002Fhebei","050000","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.17968,25.93504,{"lat":48,"lon":47},[51],{"name":52,"role":30,"phone":53,"phoneExt":32,"email":33},"hui bu, phd","13831106903",{"facility":25,"status":38,"city":39,"state":32,"zip":32,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":57,"contacts":58},{"type":45,"coordinates":56},[47,48],{"lat":48,"lon":47},[59],{"name":60,"role":30,"phone":53,"phoneExt":32,"email":33},"hui bu, phD",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Hui Bu","The department of neurology,clincial professor,director","100426453","phase-2-clinical-efficacy-and-safety-of-egfr-tki-combined-with-nimotuzumab-in-the-treatment-of-leptomeningeal-metastases-from-lung-cancer-100426453",false,"NCT04833205","Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer","Inclusion Criteria:\n\n* age 18 years or older, gender not limited;\n* A definite diagnosis of Leptomeningeal metastases from lung cancer, including cerebrospinal fluid cytology and\u002For neuroimaging;\n* Have a clear history of lung cancer, including histopathological diagnosis, or cytopathology combined with imaging diagnosis\n* Patients who received any of EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib etc.) meet the diagnostic criteria for secondary resistance and were in a slow progression stage\n* Detection results of cerebrospinal fluid, blood gene or lung tissue specimens showed EGFR mutation, and immunohistochemistry results of cerebrospinal fluid, blood gene or lung tissue showed positive EGFR expression\n* Bone marrow, liver, kidneys and blood clotting function are relatively stable\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group scored \\> 2 points\n* Patients had poor compliance, or for other reasons the investigator considered them unsuitable to participate in the study","ALL","18 Years",{"count":74,"type":75},30,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.",[81,82],"Leptomeningeal Metastasis","Lung Cancer",[81,84,82,21],",Nimotuzumab","UNKNOWN","2021-04-18",{"date":88,"type":89},"2021-04-20","ACTUAL",{"date":91,"type":75},"2021-04-19",{"date":93,"type":75},"2023-04-19",{"name":63,"class":6},2]